Peripheral / undifferentiated SpA
A clinical framework for peripheral phenotype, diagnostic certainty, evidence applicability and longitudinal reassessment.
Professional Essentials and selected introductory chapters are open. Access to other professional chapters follows the site’s membership policy.
Choose your starting point · clinical routes
Diagnostic uncertainty
Peripheral phenotype
Treatment decision
- 10 · Initial Management and Local TherapyProfessional access
- 11 · Conventional DMARDs: Evidence and LimitsProfessional access
- 12 · TNF Inhibition in Peripheral SpA: Direct Evidence and Early-Disease TrialsProfessional access
- 13 · Beyond TNF: Direct Evidence, Mixed Populations and ExtrapolationProfessional access
- 14 · Choosing Treatment Across Organ DomainsProfessional access
Persistent symptoms
- 15 · Diagnostic Evolution and ReassessmentProfessional access
- 16 · Persistent Symptoms: Active Inflammation, Damage or Another Problem?Professional access
- 17 · Remission, Treatment Reduction and Drug-Free Disease ControlProfessional access
- 18 · Long-Term Outcomes, Function and PrognosisProfessional access
Evidence and future directions
Chapters
No chapters match these filters. Try a broader search or select Reset.
Definitions and disease framework
Chapter 1: Peripheral SpA, PsA, uSpA and Diagnostic Boundaries
Separate peripheral phenotype, disease association and diagnostic confidence before choosing a treatment pathway or interpreting a study.
Open accessChapter 2: Epidemiology and Clinical Heterogeneity
Read peripheral SpA epidemiology through its denominator, classification method and referral setting; avoid turning cohort proportions into patient predictions.
Professional accessChapter 3: Peripheral Tissue Biology and Therapeutic Targets
Connect synovium, enthesis, dactylitis and bone responses to therapeutic targets while keeping mechanistic plausibility separate from clinical efficacy.
Professional access
Diagnosis and phenotyping
Chapter 4: Phenotyping Across Peripheral and Extra-musculoskeletal Domains
Build a reproducible domain record that distinguishes active inflammation, prior disease and functional impact before choosing treatment.
Open accessChapter 5: Diagnosis, Classification and the 2025 ASAS–SPARTAN Revised Axial Criteria
Use peripheral and axial classification in their intended populations, with explicit criteria versions and a separate clinical diagnostic judgment.
Open accessChapter 6: Differential Diagnosis and Important Mimics
Prioritize dangerous and plausible alternatives to peripheral SpA by the presenting problem: hot joint, persistent synovitis, enthesis pain or swollen digit.
Open accessChapter 7: Testing That Changes Management
Choose laboratory and synovial-fluid tests by the decision they address: infection, crystals, competing disease, inflammatory burden or treatment safety.
Professional accessChapter 8: Imaging in Clinical Context: Ultrasound, MRI and Radiography
Choose imaging by the tissue and decision, interpret inflammatory and structural lesions together, and understand what DEUS can and cannot establish.
Professional access
Measurement
Chapter 9: Measuring Peripheral Arthritis, Enthesitis, Dactylitis and Patient Impact
Use DAPSA44 for its intended peripheral arthritis domain and complement it with enthesis, dactylitis, organ and patient-impact assessments.
Open access
Treatment
Chapter 10: Initial Management and Local Therapy
Build an initial peripheral SpA plan around confirmed inflammation, safe local care, rehabilitation and clear reassessment triggers.
Professional accessChapter 11: Conventional DMARDs: Evidence and Limits
Read sulfasalazine, methotrexate and leflunomide evidence by population and manifestation, with practical rules for response and reassessment.
Professional accessChapter 12: TNF Inhibition in Peripheral SpA: Direct Evidence and Early-Disease Trials
Compare ABILITY-2, CRESPA and SPARTACUS by population, study design, publication status and the clinical question each can answer.
Professional accessChapter 13: Beyond TNF: Direct Evidence, Mixed Populations and Extrapolation
Distinguish IL-17, IL-23, JAK and TYK2 evidence by population, including 2026 PsA developments and limits in nonpsoriatic pSpA.
Professional accessChapter 14: Choosing Treatment Across Organ Domains
Choose peripheral SpA treatment across joints, entheses, skin, bowel, eyes and axial disease, with explicit safety and evidence boundaries.
Professional access
Longitudinal care
Chapter 15: Diagnostic Evolution and Reassessment
Reassess peripheral SpA over time: distinguish newly apparent disease associations, changing phenotype and an alternative diagnosis.
Professional accessChapter 16: Persistent Symptoms: Active Inflammation, Damage or Another Problem?
Assess persistent symptoms by separating inflammation, damage, mechanical load, alternative disease and other pain contributors.
Professional accessChapter 17: Remission, Treatment Reduction and Drug-Free Disease Control
Define peripheral SpA remission carefully and distinguish dose reduction, withdrawal and drug-free control using the CRESPA evidence.
Professional accessChapter 18: Long-Term Outcomes, Function and Prognosis
Discuss peripheral SpA prognosis through inflammatory control, function, participation and diagnostic evolution without deterministic predictions.
Professional access
Safety and special populations
Chapter 19: Treatment Safety, Infection, Vaccination, Surgery and Coordinated Care
Build a drug-specific safety plan for peripheral SpA, including infection screening, vaccination, surgery and shared specialty care.
Professional accessChapter 20: Pregnancy, Lactation, Older Age and Multimorbidity
Adapt peripheral SpA decisions for reproduction, older age and comorbidity using drug-specific evidence and coordinated care.
Professional accessChapter 21: Juvenile-onset Disease Entering Adult Care
Transfer juvenile-onset SpA into adult care with a preserved disease history, current phenotype and uninterrupted monitoring.
Professional access
Evidence and future directions
Chapter 22: Reading the Peripheral SpA Evidence Base
Read peripheral SpA studies by separating population applicability, study design, publication status and the clinical decision supported.
Professional accessChapter 23: Biomarkers and Precision Phenotyping
Distinguish diagnostic, prognostic and predictive biomarkers from exploratory findings, and assess whether a test changes peripheral SpA care.
Professional accessChapter 24: Early Intervention and Disease Modification
Assess the peripheral SpA window-of-opportunity hypothesis using CRESPA and SPARTACUS without equating early response with disease modification.
Professional accessChapter 25: Emerging Therapies and the Research Agenda
Explore the peripheral SpA research questions that could change care, with current trial status and explicit separation from PsA-derived evidence.
Professional access
Professional quizzes
Apply the collection in short clinical cases. Open demos need no registration; standard quizzes use Professional membership, an active pass or a redeemed access code.
20 quizzes · English
PSPA-PRO-QUIZ-01 · English · Open demo
One Label, Three Questions
Phenotype, disease context and diagnostic confidence in peripheral and undifferentiated SpA. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-02 · English · Open demo
The Domain Record
Phenotyping arthritis, entheses, dactylitis and extra-musculoskeletal disease before choosing treatment. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-03 · English · Professional access
Criteria in Their Place
Peripheral and axial classification, the 2025 ASAS–SPARTAN revision and the separate task of clinical diagnosis. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-04 · English · Professional access
Before You Call It a Flare
Infection, crystals, other inflammatory disease and mechanical mimics of peripheral SpA. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-05 · English · Professional access
Reading the Score
DAPSA44, enthesitis and dactylitis measures, and what a number does and does not say about the patient. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-06 · English · Professional access
First Moves
Local therapy, NSAIDs, glucocorticoids and rehabilitation at the start of peripheral SpA care. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-07 · English · Professional access
The Limits of Conventional DMARDs
Sulfasalazine, methotrexate and leflunomide: what the trials tested and what they did not. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-08 · English · Professional access
Three Trials, Three Questions
ABILITY-2, CRESPA and SPARTACUS: what each TNF-inhibitor trial can and cannot tell you. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-09 · English · Professional access
Borrowed Evidence
IL-17, IL-23, JAK and TYK2 inhibition: direct, PsA-derived and extrapolated evidence in peripheral SpA. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-10 · English · Professional access
One Patient, Several Organs
Choosing treatment when joints, entheses, skin, bowel, eyes and reproductive plans compete. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-11 · English · Professional access
When the Label Moves
Reassessing peripheral SpA over time: new associations, a changing phenotype and alternative diagnoses. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-12 · English · Professional access
Still Hurting
Persistent symptoms: separating ongoing inflammation, damage, mechanical load, another disease and other pain contributors. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-13 · English · Professional access
Stepping Down
Defining remission, and distinguishing dose reduction, withdrawal and drug-free disease control. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-14 · English · Professional access
What Will Happen to Me?
Prognosis as a set of trajectories: inflammatory control, function, participation and treatment burden. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-15 · English · Professional access
The Safety Plan
Infection screening, acute illness, vaccination, surgery and shared care around immunomodulatory treatment. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-16 · English · Professional access
What Was Counted?
Denominators, case definitions and referral settings behind the numbers quoted for peripheral SpA. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-17 · English · Professional access
From Pathway to Prescription
What tissue biology can and cannot tell you about treating synovium, enthesis and digit. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-18 · English · Professional access
A Test for a Decision
Choosing laboratory, microbiological and safety tests by the decision each one is meant to serve. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-19 · English · Professional access
Reading the Image in Context
Ultrasound, MRI and radiography: lesion, technique and the limits of what a study establishes. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
PSPA-PRO-QUIZ-20 · English · Professional access
When Circumstances Change the Plan
Pregnancy, lactation, paternal exposure, older age, cardiovascular risk and a history of cancer. Case-based self-assessment for healthcare professionals.
Open the quiz →Reviewed
No matching quizzes. Clear the search or change access.